VANDA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.62 USD | +3.12% |
|
-9.59% | +9.48% |
| Apr. 25 | Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer | RE |
| Apr. 22 | Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court | MT |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is Jeannie, and I will...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +9.48% | 266M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VNDA Stock
- News Vanda Pharmaceuticals Inc.
- Transcript : Vanda Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 07, 2024
